SQZ Biotechnologies Company is a
clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients
around the world. The company has active programs in oncology, autoimmune and infectious diseases, as well as
additional exploratory initiatives to support future pipeline growth. SQZ’s proprietary Cell Squeeze® technology
can deliver multiple biological materials into many cell types, offering the ability to engineer a broad range
of potential therapeutics.
With clinical production timelines
already under 24 hours, the company has the potential to enable broader patient accessibility through
point-of-care manufacturing implementation across multiple therapeutic programs. The company's approach
could also improve a patient’s treatment journey with no planned hospitalization or preconditioning treatment.
The company’s first therapeutic efforts seek to generate target-specific immune responses, both through
activation for the treatment of solid tumors and infectious diseases, and by immune tolerance for the treatment
of autoimmune diseases.
Learn more: SQZ Investor Factsheet